Intraocular Pressure Monitoring Using an Intraocular Sensor Before and After Glaucoma Surgery

PURPOSE Intraocular pressure (IOP) is the only modifiable risk factor for glaucoma, with evidence from landmark randomized controlled trials demonstrating visual field preservation with IOP reduction. Over recent years, the use of remote sensors has formed an increasingly important component of the management of chronic diseases. During the COVID-19 pandemic, the ability to remotely monitor IOP proved particularly useful when public stay at home orders have been in place. PATIENTS AND METHODS This report describes the first case of glaucoma surgery in a patient who had previously received an eyemate-IO implant. The eyemate-IO (Implandata Ophthalmic Products) is an implant for intraocular pressure (IOP) monitoring placed in the ciliary sulcus during cataract surgery. RESULTS Remote IOP monitoring enabled the clinician to identify sustained high IOP readings and the need for glaucoma surgery. Post-operatively, response to treatment could be monitored to ensure sufficient long-term IOP control. CONCLUSIONS The eyemate-IO implanted during cataract surgery in this patient provided valuable remote continuous IOP information that guided timely glaucoma surgical interventions for poorly controlled IOP.

[1]  R. Weinreb,et al.  Intraocular Pressure Telemetry for Managing Glaucoma during the COVID-19 Pandemic , 2020, Ophthalmology Glaucoma.

[2]  A. Tatham,et al.  Self-monitoring of intraocular pressure in glaucoma , 2019, Expert Review of Ophthalmology.

[3]  H. Thieme,et al.  Telemetric measurement of intraocular pressure via an implantable pressure sensor - twelve-month results from the ARGOS-02 trial. , 2019, American journal of ophthalmology.

[4]  C. Chiquet,et al.  24-h monitoring devices and nyctohemeral rhythms of intraocular pressure , 2016, Progress in Retinal and Eye Research.

[5]  Richard A. Russell,et al.  Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.

[6]  P. Walter,et al.  Implantation of a novel telemetric intraocular pressure sensor in patients with glaucoma (ARGOS study): 1-year results. , 2015, Investigative ophthalmology & visual science.

[7]  A. Rotchford,et al.  Repeatability of measurements of effectiveness of glaucoma medication , 2012, British Journal of Ophthalmology.

[8]  S. Melki,et al.  Intraocular pressure measurement by radio wave telemetry. , 2011, Investigative ophthalmology & visual science.

[9]  Philip P. Chen,et al.  The Effect of Early Posttrabeculectomy Intraocular Pressure Spike in the Collaborative Initial Glaucoma Treatment Study , 2011, Journal of glaucoma.

[10]  P. Khaw,et al.  Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. , 2010, Ophthalmology.

[11]  M. C. Leske,et al.  Predictors of long-term progression in the early manifest glaucoma trial. , 2007, Ophthalmology.

[12]  P. Khaw,et al.  Anterior chamber flare after trabeculectomy and after phacoemulsification , 2000, The British journal of ophthalmology.

[13]  C. O'brien,et al.  Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. , 1994 .

[14]  C. O'brien,et al.  Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. , 1994 .